The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts
- 1 May 2015
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 135 (5) , e1131-e1140
Abstract
BACKGROUND: Despite widespread promotion of quadrivalent human papillomavirus (qHPV) vaccination for young girls, there is limited information on the vaccine’s real-world effectiveness and none on the effectiveness of qHPV vaccination programs. We assessed the impact of the qHPV vaccine and Ontario’s grade 8 qHPV vaccination program on cervical dysplasia and anogenital warts (AGW). METHODS: By using administrative health databases of Ontario, Canada, we identified a population-based retrospective cohort of girls in grade 8 before (2005/2006–2006/2007) and after (2007/2008–2008/2009) program implementation. Vaccine exposure was ascertained in grades 8 to 9 and outcomes in grades 10 to 12. A quasi-experimental approach known as regression discontinuity was used to estimate absolute risk differences (RDs), relative risks (RRs), and 95% confidence intervals (CIs) attributable to vaccination and program eligibility (intention-to-treat analysis). RESULTS: The cohort comprised 131 781 ineligible and 128 712 eligible girls (n = 260 493). We identified 2436 cases of dysplasia and 400 cases of AGW. Vaccination significantly reduced the incidence of dysplasia by 5.70 per 1000 girls (95% CI −9.91 to −1.50), corresponding to a relative reduction of 44% (RR 0.56; 95% CI 0.36 to 0.87). Program eligibility also had a significant protective effect on dysplasia: RD −2.32/1000 (95% CI −4.02 to −0.61); RR 0.79 (95% CI 0.66 to 0.94). Results suggested decreases in AGW attributable to vaccination (RD −0.83/1000, 95% CI −2.54 to 0.88; RR 0.57, 95% CI 0.20 to 1.58) and program eligibility (RD −0.34/1000, 95% CI −1.03 to 0.36; RR 0.81, 95% CI 0.52 to 1.25). CONCLUSIONS: This study provides strong evidence of the early benefits of qHPV vaccination among girls aged 14 to 17 years, offering additional justification for not delaying vaccination.Keywords
This publication has 35 references indexed in Scilit:
- Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage studyBMC Medicine, 2013
- Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort StudyJNCI: Journal of the National Cancer Institute, 2013
- Human Papillomavirus Vaccine Introduction – The First Five YearsVaccine, 2012
- Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girlsBMC Public Health, 2011
- How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the U.S. Guideline Screening Initiation AgesSSRN Electronic Journal, 2011
- Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-AnalysisBMC Infectious Diseases, 2011
- A Population-Based Evaluation of a Publicly Funded, School-Based HPV Vaccine Program in British Columbia, Canada: Parental Factors Associated with HPV Vaccine ReceiptPLOS Medicine, 2010
- New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniorsJournal of Clinical Epidemiology, 2009
- Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trialsCanadian Medical Association Journal, 2007
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004